RxDoctor Payments Data

Seth Wilson, MD

Family Medicine · Sarasota, FLNPI 1518490754

Payments from drug & device makers

$7,151in general payments, 2019–2025

Across 332 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$748
  • AbbVie$682
  • Lilly USA, LLC$588
  • Novo Nordisk$498
  • Merck$496
  • Amgen$442
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,151 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$212,322
Medicare patients
636
Services billed
2,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$133,538
MounjaroTirzepatide59$73,444
EliquisApixaban68$64,641
FarxigaDapagliflozin Propanediol41$49,231
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$37,706
JardianceEmpagliflozin16$27,393
XareltoRivaroxaban18$24,822
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$19,547
Tresiba Flextouch U-100Insulin Degludec21$10,995
TrulicityDulaglutide11$10,809
EntrestoSacubitril/Valsartan15$10,592
JanuviaSitagliptin Phosphate11$10,216
Atorvastatin Calcium591$5,267
Testosterone17$3,883
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$498$133,53874 claims
Lilly USA, LLCMounjaro, Trulicity$588$84,25370 claims
AstraZenecaFarxiga, Breztri Aerosphere$362$68,77865 claims
PfizerEliquis, Paxlovid$748$66,07185 claims
GSKTrelegy Ellipta$321$37,70623 claims
Boehringer IngelheimJardiance$53$27,39316 claims
Johnson & JohnsonXarelto$48$24,82218 claims
NovartisEntresto$248$10,59215 claims
MerckJanuvia$496$10,21611 claims
AbbVieSynthroid$682$3,29042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →